Categories
Change Password!
Reset Password!
In people with COVID-19 and concomitant ACS, the composite outcome of myocardial infarction, mortality, and early stent thrombosis was not distinct between Clopidogrel and Ticagrelor.
In individuals who presented with acute coronary syndromes (ACS) and active COVID-19, who were treated with urgent coronary angioplasty, Ticagrelor in comparison with Clopidogrel did not considerably reduce myocardial infarction, all-cause mortality, or early stent thrombosis in 30-day follow-up, according to the findings of a randomized clinical trial.
ACS-affected patients are more prone to experience negative clinical outcomes when they have an acute COVID-19 disease. This multicenter study sought to examine influence of Clopidogrel and Ticagrelor on the short-term outcomes of these patients because some studies revealed enhanced lung function with Ticagrelor.
Overall, 180 COVID-19 people with ACS who underwent urgent percutaneous coronary intervention (PCI) were randomized to get Ticagrelor (180 mg loading dose followed by 90 mg twice daily, n=90) or Clopidogrel (600 mg loading dose with 75 mg daily, n=90), and they were then monitored for one month following their procedure. Early stent thrombosis, all-cause mortality, and myocardial infarction during the first month following stent implantation was the key composite outcome.
The key composite endpoint was non-significantly reduced in the Ticagrelor group compared to the Clopidogrel group following 30 days of follow-up (18.5% vs 23.5% respectively). The mean survival rates were higher in the Ticagrelor group according to the time-to-event analysis. The secondary outcomes were comparable in the study groups, with the exception of the mean oxygen saturation, which was greater in the Ticagrelor group, as illustrated in Table 1:
The composite result of mortality, myocardial infarction, and early stent thrombosis among coronavirus-infected patients with concurrent ACS who were treated with urgent PCI did not differ between the Ticagrelor and Clopidogrel groups. Ticagrelor use was linked with a slight but considerable rise in oxygen saturation compared to Clopidogrel. However, this difference was not clinically vital.
Archives of Academic Emergency Medicine
Effect of Ticagrelor Compared to Clopidogrel on Short-term Outcomes of COVID-19 Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention; a Randomized Clinical Trial
Reza Arefizadeh et al.
Comments (0)